UBS analyst Alice Nettleton initiates coverage on Ocular Therapeutix (NASDAQ: OCUL) with a Buy rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage